Burks, J., Tiwary, S., Stevens, D. M., Skoczen, S. L., Kularatne, R. N., Stern, S. T., Berzofsky, J. A.

Background
The prototypical type I natural killer T (NKT) cell agonist, α-galactosylceramide (α-GalCer), has shown only minimal effects against solid tumors in the clinic. The most promising clinical application of α-GalCer currently…